Daniel Hering, APRN
Nurse Practitioner · Las Vegas, NVNPI 1518203512
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AstraZeneca at 26.9% of the total. Among nurse practitioner clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 144 payments — averaging $45.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- United Therapeutics Corporation$973
- Mylan Specialty L.p.$590
- Sanofi$538
- GSK$514
- Actelion Pharmaceuticals US, Inc.$459
- plus $2K from 12 others
What the payments were for
- Food & beverage$6,619100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $1,779 |
| United Therapeutics Corporation | 9 | $973 |
| Mylan Specialty L.p. | 6 | $590 |
| Sanofi | 6 | $538 |
| GSK | 24 | $514 |
| Actelion Pharmaceuticals US, Inc. | 6 | $459 |
| Regeneron Healthcare Solutions, Inc. | 11 | $356 |
| Boehringer Ingelheim | 16 | $329 |
| Baxter Healthcare | 4 | $298 |
| Electromed, Inc. | 3 | $205 |
| Amgen | 5 | $199 |
| Mylan Inc. | 1 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Verona Pharma, Inc. | 2 | $62 |
| Insmed, Inc. | 1 | $53 |
| Novartis | 2 | $30 |
| Biocryst US Sales Co., LLC | 1 | $21 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,619 in reported general payments places this provider in the 95th percentile of 933 nurse practitioner providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 572 | $471,943 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 105 | $81,045 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 109 | $69,120 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 112 | $67,415 |
| SymbicortBudesonide/Formoterol Fumarate | 198 | $61,652 |
| Spiriva RespimatTiotropium Bromide | 69 | $51,099 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $30,775 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $15,825 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $6,449 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 282 | $5,525 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,841 |
| Roflumilast | 16 | $2,240 |
| Azelastine Hcl | 11 | $672 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $605 |
| Fluticasone Propionate | 28 | $502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $514 | $587,663750 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,779 | $149,146316 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $329 | $118,514181 claims |
| Mylan Inc.Wixela Inhub | $127 | $60511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 nurse practitioner providers in Nevada.
Other nurse practitioner in Las Vegas
- Melanie SpeedLas Vegas$80K
- Shelley MilesLas Vegas$34K
- Nasslynne LenzLas Vegas$32K
- Shannon SouthwickLas Vegas$32K
- Bonnie KwanLas Vegas$30K
- Amanda RalphLas Vegas$26K
- Teodoro AgtayLas Vegas$25K
- Katherine WhitmireLas Vegas$18K
- Jennifer WalshLas Vegas$18K
- Andrew VolinLas Vegas$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.